Mitxelena, A., & Areses, M. (2022). Bezlotoxumab can reduce the risk of Clostridium Difficile recurrence. Osagaiz: Osasun-Zientzien Aldizkaria, 6(1). Retrieved from https://aldizkariak.ueu.eus/index.php/osagaiz/article/view/362